0001415889-24-015587.txt : 20240605
0001415889-24-015587.hdr.sgml : 20240605
20240605165742
ACCESSION NUMBER: 0001415889-24-015587
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240603
FILED AS OF DATE: 20240605
DATE AS OF CHANGE: 20240605
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wassil Jim
CENTRAL INDEX KEY: 0001813798
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39323
FILM NUMBER: 241022772
MAIL ADDRESS:
STREET 1: C/O VAXCYTE, INC.
STREET 2: 353 HATCH DRIVE
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vaxcyte, Inc.
CENTRAL INDEX KEY: 0001649094
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464233385
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 650-837-0111
MAIL ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
FORMER COMPANY:
FORMER CONFORMED NAME: SutroVax, Inc.
DATE OF NAME CHANGE: 20150724
4
1
form4-06052024_080638.xml
X0508
4
2024-06-03
0001649094
Vaxcyte, Inc.
PCVX
0001813798
Wassil Jim
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, STE. 300
SAN CARLOS
CA
94070
false
true
false
false
CHIEF OPERATING OFFICER
1
Common Stock
2024-06-03
4
S
0
1634
71.384
D
214869
D
Common Stock
2024-06-03
4
S
0
906
72.319
D
213964
D
Common Stock
2024-06-03
4
S
0
460
73.475
D
213503
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 23, 2023.
The price reported is a weighted-average price. The shares were sold at prices ranging from $70.98 to $71.94. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
Includes 1,041 shares acquired under the Issuer's Employee Stock Purchase Plan on May 17, 2024.
The price reported is a weighted-average price. The shares were sold at prices ranging from $72.01 to $72.67. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The price reported is a weighted-average price. The shares were sold at prices ranging from $73.41 to $73.54. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
/s/ Ron A. Metzger, Attorney-in-Fact
2024-06-05